CDKN2A and melanoma: The ribociclib and binimetinib combination has demonstrated effectiveness in NRAS‐mutated melanoma, especially in patients with additional cell cycle gene mutations (CDKN2A, CDK4, and CCND1), who may derive greater benefit from this therapy [42].